Mobia Medical, Inc.
Mobia Medical, Inc. is a commercial-stage medical device company focused on neurostimulation solutions for neurological rehabilitation. Its flagship Vivistim Paired Vagus Nerve Stimulation system is an FDA-approved implantable therapy designed to support upper limb motor recovery in people living with chronic ischemic stroke and related motor impairments. The company develops, markets, and sells devices that combine vagus nerve stimulation with structured therapy to promote neuroplasticity and functional improvement. Mobia Medical serves stroke centers and healthcare providers involved in post-stroke rehabilitation, with its products positioned within the medical devices sector as specialized tools for chronic neurological care. Founded in 2007 and headquartered in Austin, Texas, Mobia Medical plays a focused role in the recovery technology market by offering clinically validated treatment options for patients with persistent movement limitations.
$8.09
-$0.22 (-2.65%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-144.71% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 104.8% YoY with margins expanding 10.2pp.
ROIC dropped from -247.99% to -453.46%, capital efficiency is deteriorating. Negative free cash flow of -$46M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$32M
▲ +104.8% YoY
Net Income (FY)
-$46M
▼ -89.0% YoY
Op. Margin
-144.71%
▲ +10.2pp YoY
ROIC
-453.46%
▼ -205.5pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$46M
▼ -89.1% YoY
Op. Cash Flow (FY)
-$46M
▼ -87.9% YoY
Net Debt
-$25M
Net Cash Position
Cash & Equiv.
$34M
Continue Research
Is Mobia Medical (MOBI) overvalued?
Mobia Medical (MOBI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Mobia Medical scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Mobia Medical a high-quality business?+
Mobia Medical scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -144.7% operating margin and a -453.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Mobia Medical a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh MOBI's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Devices
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.